We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Drug-Resistant Bacteria Can Raise Sepsis Risk

By LabMedica International staff writers
Posted on 11 May 2017
Sepsis affects an estimated 30 million people worldwide each year and without quick treatment, it can lead to multiple organ failure and death. More...
Treating sepsis can be even more difficult if the bacteria responsible are resistant to antibiotics.

In some cases bacteria may be spreading from the bowel or urinary tract into the bloodstream, while in others the bacteria found in patients’ urine or stool samples could be transferring their ability to resist antibiotics to other bacteria in the body, which then can cause sepsis.

Scientists at the Karolinska Institutet studied 66,000 people and showed that the risk of drug resistant sepsis is highest soon after drug resistant bacteria have been detected in a patient’s urine or stool, and that this risk diminishes over time. They say their findings could help doctors diagnose drug resistant sepsis and inform treatment choices. The team studied all subjects who were found to have specific types of bacteria in their urine or stool samples in Sweden between 2007 and 2012, more than 22,000 in total. They compared them with an equivalent group of 44,000 people who had no diagnosis of extended-spectrum β-lactamase-producing Enterobacteriaceae (EPE).

The investigators focused on certain bacteria, such as Escherichia coli, that produce enzymes called extended spectrum β-lactamases. These enzymes allow bacteria to break down a variety of antibiotics including penicillin and third-generation cephalosporins. They followed the subjects for six years to find out if they subsequently developed a bloodstream infection. The data revealed that people whose bowels had been colonized previously by EPE were 57 times more likely to develop an EPE infection of the bloodstream, compared to the general population. For those with a previous finding of EPE in their urine, the risk was 113 times higher than the general population. Over the six-year study period, 2% of those with EPE in the bowel and 4% of those with a urinary tract infection went on to have a bloodstream infection with EPE. This compares to 0.02% in the general population.

Joakim Isendahl, MD, who presented the study said, “Knowing if a patient has had a previous finding of EPE, and how long ago it was, helps inform doctors on when last-­resort drugs are essential, but also on when they are not needed. This is important since prudent use is imperative to keep them effective. We found that the riskiest time was in the days and weeks after the bacteria were found in the urine or stool sample, but there is still an increased risk up to three years later.” The study was presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases, held April 22-25, 2017, in Vienna, Austria.


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.